ArticleThoracic cancer2025
Insight Into the Significance of CD8+ Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Insight Into the Significance of CD8+ Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma.Thoracic cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite great expectations regarding the use of tumor-infiltrating lymphocytes (TILs) in predicting the effects of immunotherapies and prognosis, knowledge about TILs remains inadequate for clinical application. We re-evaluated the clinicopathological significance of CD8+ tumor-infiltrating lymphocytes (CD8 + TILs) in lung adenocarcinoma from a novel perspective and through a more objective approach using cell counting software.
methodsAmong patients with surgical resection of lung adenocarcinoma in 2011-2017, 156 patients with pathological stage IB-III were immunohistochemically studied to evaluate CD8 + TILs in the tumor stroma. The impact of CD8 + TILs on relapse-free survival was analyzed by Kaplan-Meier survival and multivariate Cox proportional hazards analyses.
resultsOur analysis showed that patients with large numbers of CD8 + TILs in the stroma are not a homogeneous population and include subpopulations with a poor prognosis. Furthermore, our study showed important findings about the overall inflammatory status in the tumor microenvironment based on the association between the number of CD8 + TILs and the frequency of vascular invasion. Additionally, CD8 + TILs were shown to potentially be more effective than PD-L1.
conclusionsOur study demonstrated that in lung adenocarcinoma, even among populations with abundant CD8 + TILs in the tumor stroma, there may be a poor prognostic subgroup. Furthermore, we revealed a partial yet important relationship between CD8 + TILs and the tumor microenvironment. A more detailed investigation into the significance of CD8 + TILs may lead to a deeper understanding of the inflammatory status of the tumor microenvironment and ultimately contribute to the identification of appropriate biomarkers for prognostic prediction and assessing the efficacy of immune checkpoint inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.